



SHTG Recommendation: Tumour profiling tests to guide adjuvant chemotherapy decisions for patients with early breast cancer

| Name | Date of declaration | Project element | 2.1 Personal Financial interests for the past three years | 2.2 Non-personal Financial interests for the past year (12 months) | 2.3 Personal non-financial interests | 2.4 Non-personal non-financial interests | 2.5 Any other interests which could be perceived to affect your impartiality |
|---|---------------------|-----------------|--|--|--|--|--|
| Heather Rankine Business Lead Scotland and Northern Ireland, Exact Sciences Ltd | 01/06/2023 | Peer review | Exact Sciences Employee- ongoing interest Specific to topic - Yes | None | Health condition Ongoing interest Specific to topic - Yes | None | None |
| Rosemary Stevens Consultant Clinical Oncologist GMC/Royal College of Radiologists | 31/05/2023 | Peer review | None | None | None | None | None |

| | | | | | | | |
|---|------------|----------------|--|-------------|-------------|-------------|--|
| Adrian Wood Country Manager UK, Veracyte | 30/05/2023 | Peer review | Veracyte Employee – ongoing interest Commercial Prosigna Specific to topic - Yes | None | None | None | None |
| Sandra Auld Director of Healthcare Public Affairs Public Partner and Service User for Perth & Kinross IJB | 26/05/2023 | Peer review | Exact Sciences Ongoing interest Specific to topic – Yes Abbvie Ongoing interest Specific to topic - No | None | None | None | Heathcare Public Affairs Thank you for the opportunity to participate and contribute. HPA Is a Health policy and public affairs consultancy. I have listed the clients over the past 3 years whose interests I am aware of in the breast cancer arena. I provided health policy advice to Exact Sciences relating to their SHTG submission on this topic. |
| Jelle Klinkhammer Market Access | 26/05/2023 | Peer review | Agendia NV Ongoing interest – employee | None | None | None | None |

| | | | | | | | |
|--|------------|-------------|--|---|------|------|------|
| Manager Europe | | | Specific to topic - Yes | | | | |
| Agendia NV | | | | | | | |
| Professor Robert Van Der Meer Professor of Management Science, University Of Strathclyde | 18/05/2023 | Peer review | Exact Sciences Ongoing Interest - fee for consultancy Specific to topic – Yes University of Strathclyde Ongoing interest – publishing research papers Specific to topic - Yes | Pancreatic Cancer UK Research Grant Date interest ceased - 31/10/22 Specific to topic – No Cancer Research UK Ongoing interest - research grant Specific to topic – No NHS Golden Jubilee Ongoing interest - research grant Specific to topic – No NHS Lanarkshire Ongoing interest - research grant | None | None | None |

| | | | | | | | |
|--|------------|---------------------------------|-------------|---|---|-------------|-------------|
| | | | | <p>Specific to topic – No</p> <p>NHS Greater Glasgow & Clyde</p> <p>Ongoing interest - research grant</p> <p>Specific to topic - No</p> | | | |
| <p>Dr Noelle O'Rourke</p> <p>National Clinical Lead, Scottish Cancer Network,</p> | 12/05/2023 | Peer review | None | None | None | None | None |
| <p>Peter Hall</p> <p>Medical Oncologist, University of Edinburgh/ NHS Lothian</p> | 12/05/2023 | Topic Expert at Council Meeting | None | <p>SeaGen</p> <p>Ongoing interest - institutional research funding</p> <p>Specific to topic – No</p> <p>Gilead</p> <p>Ongoing interest - institutional research funding</p> | <p>Healthcare Improvement Scotland</p> <p>Ongoing interest - Chair or member of various guideline development, governance and advisory groups e.g. SCN, SMC, formulary committee, Cancer Quality Steering group etc.</p> | None | None |

| | | | | | | | |
|--|--|--|--|--|---|--|--|
| | | | | <p>Specific to topic - No</p> <p>Eisai</p> <p>Ongoing interest - institutional research funding</p> <p>Specific to topic – No</p> <p>Lilly</p> <p>Ongoing interest - institutional research funding</p> <p>Specific to topic – No</p> <p>Novartis</p> <p>Ongoing interest - institutional research funding</p> <p>Specific to topic – No</p> <p>AstraZeneca</p> <p>Ongoing interest - institutional research funding</p> | <p>Specific to topic - Yes</p> <p>NA</p> <p>Ongoing interest - co-author on various publications and research reports that include various of the comparator genomic tests.</p> <p>Specific to topic - Yes</p> | | |
|--|--|--|--|--|---|--|--|

Specific to topic –
No

NIHR

Ongoing interest -
institutional research
funding

Specific to topic –
No

MRC

Ongoing interest -
institutional research
funding

Specific to topic –
No

**Cancer Research
UK**

Ongoing interest -
institutional research
funding

Specific to topic –
No

| | | | | | | | |
|--|------------|-------------|---|------|------|------|------|
| | | | | | | | |
| Dr Caroline Michie Consultant Medical Oncologist, Edinburgh Cancer Centre | 09/06/2023 | Peer review | AstraZeneca Ongoing interest – financial Specific to topic – No Novartis Financial interest ceased - May 2023 Specific to topic – No Seagen Financial interest ceased - May 2023 Specific to topic – No Roche Financial interest ceased - November 2022 Specific to topic – No Pfizer Financial interest ceased - June 2023 | None | None | None | None |

| | | | | | | |
|---|------------|----------------|---|---|--|--|
| | | | <p>Specific to topic – No</p> <p>Exact Sciences</p> <p>Financial interest ceased – February 2023</p> <p>Specific to topic - Yes</p> <p>Gilead</p> <p>Interest – Ongoing financial interest</p> <p>Specific to topic – No</p> <p>Eli Lilly</p> <p>Financial interest ceased – June 2023</p> <p>Specific to topic - No</p> | | | |
| <p>Professor David Cameron</p> <p>Professor for Oncology</p> | 14/06/2023 | Peer Review | None | <p>Exact Sciences</p> <p>Ceased financial interest – payment to employer in 2022</p> | | <p>Veracyte</p> <p>Ongoing - Research support to a trial run elsewhere that</p> |

| | | | | | | | |
|---|------------|--|-------------|---|---|--|---|
| Edinburgh Cancer Centre | | | | Specific to topic - Yes Exact Sciences Ceased financial interest - Bought a company PFS with whom we had a research collaboration in 2023. Specific to topic - No | | I am a member on. Specific to topic - Yes | |
| Anne-Marie Barry Policy and Public Affairs Lead, Breast Cancer Now | 14/06/2023 | Patient Org Submission and attended the Council meeting. | None | None | None | None | None |
| Prof. Lee B. Jordan Consultant Cellular (Breast) Pathologist, NHS Tayside | 15/06/2023 | Peer Review | None | None | Published meeting works (Peters AL, Elsberger B, Hall P, Jordan LB, Soh FY, Hannington L, Makaranka S, Urquhart G, Vallet M, Cartwright D, Marashi H. Clinical application of a genomic tool for decision support in breast cancer patients | None | NHS Tayside Practising consultant pathologist who utilises genomic testing in day-to-day clinical practice at the request of service users (oncologists & surgeons) and by the mandate of Scottish Government |

| | | | | | |
|--|--|--|--|--|--|
| | | | | <p>in Scotland. In: European Society for Medical Oncology Congress 2022; 9th-13th September 2022; Paris, France; ESMO; September 2022. Abstract 82P. Available from: Ann Surg Oncol 2022; 33(Suppl.3): S159</p> <p>Specific to topic – Yes</p> <p>Published meeting works (Peters AL, Marashi H, Hall P, Jordan LB, Soh FY, Hannington L, Markaranka S, Urquhart G, Vallet M, Cartwright D, Elsberger B. Steroid receptor positivity and tumour type are influencing Oncotype Dx recurrence score and subsequent treatment delivery in Scotland. In: Association of Breast Surgery Conference 2022; 16th-17th May 2022; Liverpool, UK; ABS; May 2022. Abstract P175. Available from: Eur J</p> | <p>via various public bodies.</p> <p>Specific to topic - Yes</p> |
|--|--|--|--|--|--|

| | | | | | | | |
|--|--|--|--|--|--|--|--|
| | | | | | <p>Surg Oncol 2022; 48: e243)</p> <p>Specific to topic – Yes</p> <p>Participation in "Scottish Consensus Statement on the use of Oncotype Dx in early Breast Cancer Management in Scotland" April 2023</p> <p>Specific to topic – Yes</p> <p>Draft publication in progress based on the mentioned meeting works</p> <p>Specific to topic – Yes</p> <p>Exact Sciences</p> <p>COVID-19 period CPD event attendee only (The Oncotype DX® test: Evolution of UK Real World Outcomes data – Update and case studies – Exact Sciences, Virtual Meeting) 27/9/2022</p> <p>Specific to topic – Yes</p> <p>Exact Sciences</p> | | |
|--|--|--|--|--|--|--|--|

| | | | | | | | |
|--|--|--|--|--|---|--|--|
| | | | | | <p>COVID-19 period CPD event attendee only (RxPONDER First Results – Exact Sciences, Virtual Meeting) 11/3/2021</p> <p>Specific to topic – Yes</p> <p>Veracyte/Prosigna</p> <p>COVID-19 period CPD event attendee only (The Future of Breast Cancer Care With Genomic Profiling – ProSigna, Virtual Seminar) 15/01/2021</p> <p>Specific to topic – Yes</p> <p>Exact Sciences</p> <p>COVID-19 period CPD event attendee only (Confidence in Identifying the Right Patients for Chemotherapy: The Pathologist’s Perspective – Exact Sciences, Virtual Meeting) 14/01/2021</p> <p>Specific to topic – Yes</p> <p>Wales Cancer Network</p> | | |
|--|--|--|--|--|---|--|--|

| | | | | | | |
|--|--|--|--|--|--|--|
| | | | | | <p>Attendee at Genomics Educational Event (virtual) - 01/12/2022</p> <p>Specific to topic – Yes</p> <p>Exact Sciences</p> <p>Virtual meeting with Jackie Baillie MSP (Scotland's Genomics Medicine Strategy: How do we make this a reality for cancer patients? – Exact Sciences, Virtual Meeting) - 07/11/2022</p> <p>Specific to topic – Yes</p> <p>NHS Scotland/Exact Sciences</p> <p>Scottish Consensus Statement Group: The Oncotype DX Breast Recurrence Score® Test – Meeting One – Institute of Genetics & Cancer, MRC, CRUK, University of Edinburgh & Exact Sciences, Virtual Meeting (links to April 2022 consensus statement. - 23/11/2021</p> | |
|--|--|--|--|--|--|--|

| | | | | | | | |
|--|------------|-------------|--|--|--|-------------|-------------|
| | | | | | <p>Specific to topic - Yes</p> <p>Multiple</p> <p>Various historic attendances at both scientific and educational national/international meetings where genomic testing and other breast cancer related activity has been discussed, debated and presented</p> <p>Specific to topic - Yes</p> | | |
| <p>Professor Rob Stein</p> <p>Professor of Breast Oncology, University College London</p> | 19/06/2023 | Peer review | <p>NIHR</p> <p>Ceased financial interest - partial salary support for role in OPTIMA clinical trial.</p> <p>Date ceased 31/03/2023</p> <p>Specific to topic - Yes</p> | <p>NIHR</p> <p>Ongoing interest - OPTIMA clinical trial.</p> <p>Specific to topic - Yes</p> | <p>NIHR</p> <p>Ongoing interest - Chief Investigator of OPTIMA clinical trial.</p> <p>Specific to topic - Yes</p> | None | None |
| <p>Steve Millen</p> <p>Director Market Access, Exact</p> | 27/06/2023 | Peer review | <p>Exact Sciences UK</p> <p>Ongoing interest – employee</p> | None | None | None | None |

| | | | | | | | |
|--|------------|-------------|----------------------------|-------------|-------------|-------------|-------------|
| Sciences UK Ltd | | | Specific to topic - Yes | | | | |
| Dr Judith Fraser Medical Oncology Consultant, Beatson West of Scotland Cancer Centre | 12/6/2023 | Peer review | None | None | None | None | None |
| Frances Yuille Consultant in Clinical Oncology, Edinburgh Cancer Centre | 05/07/2023 | Peer review | None | None | None | None | None |